Life sciences software & AI news

Showing 1000+ results

A medical report on a desk with notes and a plant in the background.

Nov 3, 2026

EVERSANA builds its AI Agency with Estima acquisition

EVERSANA has expanded its capabilities in the life sciences sector by acquiring Estima Scientific, a UK-based firm specializing in health economics and outcomes research (HEOR).This acquisition allows EVERSANA to enhance its AI Agency platform, which focuses on utilizing advanced data science tools to expedite patient access to medications. Estima employs large language models and unique software to optimize workflows related to HEOR and health technology assessments, significantly reducing the

Nov 3, 2026

Press release

QUANTRO Therapeutics secures key Austrian research grant to build its AI-powered drug discovery platform

Vienna, Austria, Nov. 03, 2026 (GLOBE NEWSWIRE) -- QUANTRO Therapeutics GmbH, a pioneer in the discovery of transcription factor targeting therapies, announced today that the company received a 12-month, non-dilutive research grant awarded by the Austrian Research Promotion Agency (Forschungsförderungsgesellschaft, FFG) to support the development of ASCEND, its AI-driven medicinal chemistry platform underpinning the company’s drug discovery pipeline. ASCEND couples QUANTRO’s capability to leve

Nov 3, 2026

Press release

Waters Acquires MOBILion Systems, Bringing Advanced Ion-Mobility Separation to its Mass Spectrometry Portfolio with the Speed and Resolution AI Workflows Require for Proteomics Biomarker Discovery

Adds MOBILion's breakthrough SLIM high-resolution ion mobility technology, which separates molecules by size, shape and charge in milliseconds, complementing Waters' industry leading mass spectrometry platform, transforming samples to insights.Accelerates Waters' move into proteomics with research capabilities built for AI foundation and frontier models, pairing the unique speed and resolution of the Xevo™ MRT MS with data generation at the scale needed to power proteomics lab-in-the-loop resear

Nov 3, 2026

Press release

LIPSIA-STRATEGY trial demonstrates non-inferiority of CAAS vFFR guided revascularization against pressure wire-based FFR revascularization

LIPSIA-STRATEGY evaluated whether revascularization guided by angiography-based FFR using CAAS vFFR (vessel Fractional Flow Reserve), delivers clinical outcomes comparable to guidance by pressure wire-based FFR.Conclusive trial results provide further randomized clinical evidence validating CAAS vFFR as a safe and effective alternative for wire-based physiology-guided revascularization.Results independently confirm the findings of FAST III, demonstrating comparable clinical outcomes while enabli

Nov 3, 2026

Press release

Differentia Bio Advances Human Digital Twins with AI-Driven Disease Modeling and Clinical Validation

From millions of molecular measurements to clinically supported therapeutic predictions, Differentia is building AI-powered disease environments for pharmaceutical R&D.SAN FRANCISCO, Nov. 3, 2026 /PRNewswire/ -- Differentia Bio, a developer of AI-powered human disease digital twins, today announced that therapeutic mechanisms identified by its disease modeling platform in 2023–2024 have since gained support from independent clinical evidence, including an FDA-approved treatment and emerging

A flat illustration of a DNA strand representing human genetic diversity.

Nov 3, 2026

Quantifying the Average Human Genome

Recent research from Exeter University sheds light on the variability of human genomes, revealing that deviation from the reference genome is not only common but expected. This study, which analyzed over 900,000 sequenced genomes, aims to establish a clearer baseline for what constitutes a "normal" human genome.The study highlights that individuals typically differ from the reference genome by approximately 4.4 to 5.2 million positions, depending on their population group. This finding challenge

Nov 3, 2026

Press release

Merck and Google Cloud Partner to Accelerate Agentic AI Enterprise Transformation

New collaboration taps Gemini Enterprise to realize business-driving value, innovation and patient impact across the next era of biopharmaceutical growthLAS VEGAS, April 22, 2026 /PRNewswire/ -- Cloud Next '26 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Google Cloud today announced a landmark partnership to enhance Merck's digital backbone as an AI-enabled enterprise. This multi-year investment, valued at up to $1 billion, will deploy an agentic platform acro

Nov 3, 2026

Press release

Variational AI Enters Collaboration with Merck to Apply Generative AI to Drug Discovery

Collaboration aims to discover and develop novel small molecule therapeutics against two targets designated by MerckVANCOUVER, British Columbia--(BUSINESS WIRE)--#AIDD--Variational AI, Inc., a generative AI drug discovery company, today announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply Variational AI’s Enki™ platform to design and optimize novel small molecule candidates against two undisclosed targets.Under the agreement, Variational AI will us

Nov 3, 2026

Press release

Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (NASDAQ: PSNL) announced today agreements with long time collaborators Merck and Moderna that accelerate the advancement of the company’s business strategy. The company has received an investment from Merck, known as MSD outside the United States and Canada, and separately has signed a multi-year extension with Moderna to utilize Personalis’ ImmunoID NeXT Platform® and technology for V940/mRNA-4157, an investigational individualized neoantigen t

Nov 3, 2026

Press release

SCIEX Launches LeadScape Compatible with SCIEX OS Software to Accelerate High-Throughput Drug Candidate Evaluation

New software automates compound optimization and ADME workflows, helping pharmaceutical scientists move from analysis to confident decisions fasterMARLBOROUGH, Mass.--(BUSINESS WIRE)--SCIEX, a Danaher company and leader in life science analytical technologies, today announced the launch of LeadScape® compatible with SCIEX OS software, a new high-throughput workflow solution that accelerates drug candidate evaluation. Developed by Sound Analytics, the software automates compound optimization and

Nov 3, 2026

Press release

Agilent Launches 5987A MSD with GC Assist for Faster, Smarter GC/MS Workflows

Single quadrupole mass selective detector delivers up to 25% faster scan speed, an order-of-magnitude improvement in dynamic range and up to 40% lower energy consumptionSANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of the 5987A single quadrupole mass selective detector (MSD) with GC Assist, along with MassHunter 14 software. When combined with the Agilent 8890B or 8860B gas chromatograph, the 5987A creates an integrated GC/MS system designed

Nov 2, 2026

Press release

Majority of Patients with Moderate Aortic Stenosis Carry Features Linked to Twice the Risk of Death, egnite Registry Study Finds

The analysis, published simultaneously in JACC, found that moderate AS patients with at least one at-risk feature had a two-fold increase in mortality and hospitalization with heart failure compared with moderate AS patients with no at-risk features over two years. Dr. Philippe Généreux also announced ACTIVATE AS, the first prospective multicenter study to use the CardioCare® platform to identify and follow patients with moderate AS.SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- In a real-world study o

Back to start
Previous
Page 5 of 84
Next

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Platform

Domains

Services

Legal